SynthesisPLoS neglected tropical diseases2026
Human gnathostomiasis - A systematic review and analysis of the literature.
Synthesis in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction: Human gnathostomiasis - A systematic review and analysis of the literature.PLoS neglected tropical diseases · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human gnathostomiasis is a foodborne zoonotic nematode infection caused by the larval stage of Gnathostoma species. Although historically reported predominantly from Asia and America, cases are increasingly identified in previously non-endemic regions. The heterogeneous clinical presentation and diagnostic challenges likely contribute to underrecognition of the global disease burden. Current evidence is largely derived from case reports and case series, with a notable lack of prospective studies. To better delineate the epidemiological distribution and clinical characteristics of human gnathostomiasis, we systematically reviewed and analyzed the available literature. Most cases are reported from Asia and the Americas, with Thailand, Japan, and Mexico accounting for the highest numbers. Clinical manifestations are predominantly larva migrans syndromes, including cutaneous involvement (83.6% of cases), followed by neurological (7.7%), ocular (3.5%), and visceral (2.3%) presentations. Long-term sequelae are uncommon overall but occur frequently in ocular (51.8%) and neurological (32.2%) disease, the latter also being associated with a substantial case-fatality rate (33.9%). Diagnosis is based on exposure risk, most commonly consumption of raw fish (70.7%), as well as laboratory findings such as eosinophilia, positive serology, and, when feasible, histopathological confirmation. Treatment primarily relies on anthelmintic treatment with albendazole and/or ivermectin and, if feasible, surgical removal of larvae. Treatment success is highest with albendazole plus ivermectin combination therapy (86.7%) compared to monotherapy with albendazole (73.5%) or ivermectin (56.7%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.